BioLife Solutions, Inc.

BioLife Solutions develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry globally. Its core offerings include proprietary biopreservation media such as HypoThermosol FRS and CryoStor Freeze Media, which are formulated to mitigate preservation-induced cell damage and death. The company also provides human platelet lysates for cell expansion, CellSeal closed system vials, CryoCase cryo-compatible containers, automated cell processing machines, and the ThawSTAR line of automated thawing devices. Additionally, it offers evo shipping containers, which are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. These products serve basic and applied research as well as commercial manufacturing of biologic-based therapies.

BioLife Solutions is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol BLFS. Its shares trade in US Dollars (USD). The company is headquartered in Bothell, Washington, United States, and its primary operations are in the US market, though it serves the global cell and gene therapy industry.

BioLife Solutions operates in the Healthcare sector, specifically within the Medical Instruments & Supplies industry. This industry classification reflects the company's focus on developing and manufacturing specialized products for the cell and gene therapy market, including biopreservation media, closed system vials, automated thawing devices, and temperature-controlled shipping containers. These products are essential tools for research and commercial manufacturing in the biopharmaceutical field.

BioLife Solutions is headquartered in Bothell, Washington, United States. The company serves the global cell and gene therapy (CGT) industry, including basic and applied research institutions and commercial manufacturers of biologic-based therapies. Its products are marketed and sold directly as well as through third-party distributors, enabling a broad reach across international markets. The company's portfolio addresses the needs of customers involved in the development and production of advanced therapies.

BioLife Solutions' main product categories include biopreservation media, such as HypoThermosol FRS and CryoStor Freeze Media, which are designed to reduce cell damage during storage and transport. The company also offers bioproduction products like human platelet lysates for cell expansion, CellSeal closed system vials, CryoCase cryo-compatible containers, and automated cell processing machines. Additionally, it provides the ThawSTAR line of automated thawing devices for frozen cell and gene therapies, and evo shipping containers—cloud-connected passive storage and transport solutions for temperature-sensitive biologics and pharmaceuticals. These products support the entire workflow from research to commercial manufacturing.